By Faith Ashmore, Benzinga
Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, potentially allowing for more efficient diagnosis, treatment and patient care. Machine learning algorithms can analyze vast amounts of data including patient medical records, genetic information and environmental factors to potentially identify patterns and predict disorders. Clinicians can also benefit from more accurate and timely diagnoses based on objective digital signals.
COMPASS Pathways (NASDAQ: CMPS) is currently developing AI-informed digital systems to assist an investigational treatment for mental health conditions, including treatment-resistant depression (TRD), anorexia nervosa and posttraumatic stress disorder (PTSD). The company is best known for its investigational psilocybin treatment and its R&D focus on mental health conditions. Its goal is to develop new and more effective treatment options for individuals with treatment-resistant depression and other difficult-to-treat mental health conditions.
The companys innovative approach has already yielded promising results, and they received FDA Breakthrough Therapy designation in the U.S. and Innovative Licensing and Access Pathway designation in the U.K. for their investigational COMP360 psilocybin treatment. In late 2021, COMPASS Pathways announced the completion of a randomized, controlled double-blind phase 2b study of COMP360 psilocybin treatment involving 233 patients with TRD in 22 sites across Europe and North America. However, the company believes that drug innovation alone is not enough to improve mental health care.
In addition to COMP360 and to better support the drug, COMPASS Pathways has developed three digital tools to help support patients and therapists to ensure the best possible treatment. While these tools will be used in tandem with the COMP360 treatment, the tools were built to be scalable and revolutionize the treatment of mental health disorders.
Therapist COMPanion is a web-based portal that supports therapists through all phases of patient care. Psilocybin administration is relatively new to providers so Therapist COMPanion acts as a tool for the provider to ensure that treatment is conducted in the right way.
myPathfinder is a patient-facing app that provides guidance throughout COMP360. The psilocybin treatment is grouped into three phases: preparation, administration and integration. COMPASS Pathways was built on the belief that patients deserve better care, especially patients who have been underserved and felt overlooked by the system after being diagnosed as treatment-resistant. This platform is an essential component of taking better care of the patient and ensuring they have the tools to understand their treatment and psilocybin experience.
However, the companys most expansive digital tool is Chanterelle, an AI and analytics infrastructure that can be used for continuous optimization throughout treatment, as well as data collection to help expand a deeper understanding of treatment-resistant disorders. The program records sessions with the patients, with their consent, and can glean a better understanding of success rates using AI and natural language processing. Chanterelle uses the BART large language model which denotes the valence and arousal of the participant and therapist to assess the emotional tenor of the conversation and to better understand if treatment is succeeding.
Chanterelles application could go beyond COMP360 and was designed to be scalable. The company is working to provide a more concrete and evidence-based way of measuring the success of treatment. While COMPASS Pathways is not the only mental healthcare company to bridge the gap between AI and care, the companys ability to design platforms that can be used for a variety of disorders sets it apart from competitors like MindMed and Medtronic.
Featured photo by Steve Johnson on Unsplash
Company BioCOMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP 360 psilocybin therapy in TRD, the largest randomised, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
View source version on newsdirect.com: https://newsdirect.com/news/how-compass-pathways-is-leveraging-ai-to-revolutionize-the-mental-healthcare-space-909410975
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Times of Chennai journalist was involved in the writing and production of this article.